US price cuts, Medicare expansion, and new oral GLP-1 approvals reshape the competitive outlook for weight-loss drugs.

AMGN's MariTide enters late-stage obesity trials with monthly dosing but faces rising competition as Eli Lilly and Novo ...

Earlier this week, the FDA approved Eli Lilly and Company’s LLY rival Novo Nordisk’s NVO oral version of the obesity drug ...

While the drugs have become spectacularly popular, their high prices, along with spotty insurance coverage, have left them ...

Dividend growth investing builds long-term wealth for retirement by focusing on companies that consistently increase payouts.

Weight-loss drugs known as GLP-1s are transforming health care. Some people who struggled for years to shed pounds experience ...

Indiana enters 2026, a major shift in the healthcare landscape is promising to make high-demand weight-loss medications more ...

The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary ...

Drugs like Ozempic, Wegovy and Zepbound have transformed how we treat obesity, but more effective treatments could be down ...

U.S. regulators this week gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

Low-income Californians who use Wegovy and similar weight loss drugs will lose their coverage in January. California and ...